Mazdutide phase 3 GLORY-2 in JAMA: 16.65% average weight loss at 60 weeks

JAMA published GLORY-2, a phase 3 trial of a higher dose of mazdutide, a weekly GLP-1 and glucagon receptor agonist approved in China, in Chinese adults with obesity. Among 461 participants, body weight fell by 16.65% at 60 weeks with mazdutide versus 1.50% with placebo, and 84.3% versus 33.1% lost at least 5% of their weight. Vomiting, nausea and diarrhoea were common, and the trial enrolled only Chinese adults.